ES2897659T3 - Formulaciones de vacunas térmicamente estables, procesos y microagujas que incluyen las formulaciones de vacunas - Google Patents

Formulaciones de vacunas térmicamente estables, procesos y microagujas que incluyen las formulaciones de vacunas Download PDF

Info

Publication number
ES2897659T3
ES2897659T3 ES14843082T ES14843082T ES2897659T3 ES 2897659 T3 ES2897659 T3 ES 2897659T3 ES 14843082 T ES14843082 T ES 14843082T ES 14843082 T ES14843082 T ES 14843082T ES 2897659 T3 ES2897659 T3 ES 2897659T3
Authority
ES
Spain
Prior art keywords
vaccine
composition
excipients
influenza
measles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14843082T
Other languages
English (en)
Spanish (es)
Inventor
Matthew Joseph Mistilis
William Christopher Edens
Andreas Sebastian Bommarius
Mark Prausnitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia Tech Research Institute
Georgia Tech Research Corp
Original Assignee
Georgia Tech Research Institute
Georgia Tech Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia Tech Research Institute, Georgia Tech Research Corp filed Critical Georgia Tech Research Institute
Application granted granted Critical
Publication of ES2897659T3 publication Critical patent/ES2897659T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
ES14843082T 2013-09-03 2014-09-03 Formulaciones de vacunas térmicamente estables, procesos y microagujas que incluyen las formulaciones de vacunas Active ES2897659T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361873032P 2013-09-03 2013-09-03
US201361873419P 2013-09-04 2013-09-04
PCT/US2014/053902 WO2015034924A1 (en) 2013-09-03 2014-09-03 Thermally stable vaccine formulations and microneedles

Publications (1)

Publication Number Publication Date
ES2897659T3 true ES2897659T3 (es) 2022-03-02

Family

ID=52628897

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14843082T Active ES2897659T3 (es) 2013-09-03 2014-09-03 Formulaciones de vacunas térmicamente estables, procesos y microagujas que incluyen las formulaciones de vacunas

Country Status (8)

Country Link
US (1) US10736840B2 (cg-RX-API-DMAC7.html)
EP (1) EP3041504B1 (cg-RX-API-DMAC7.html)
JP (2) JP6611720B2 (cg-RX-API-DMAC7.html)
CN (1) CN105579059B (cg-RX-API-DMAC7.html)
CA (1) CA2923010C (cg-RX-API-DMAC7.html)
ES (1) ES2897659T3 (cg-RX-API-DMAC7.html)
RU (1) RU2720808C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015034924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402131D0 (en) 2004-01-30 2004-03-03 Isis Innovation Delivery method
EP3881781B1 (en) 2011-10-12 2023-03-29 Vaxxas Pty Limited Delivery device
WO2015163488A1 (en) 2014-04-25 2015-10-29 Ajinomoto Co., Inc. Immunostimulating agent
CA2975275C (en) 2015-02-02 2023-08-29 Vaxxas Pty Limited Microprojection array applicator and method
US20160296149A1 (en) * 2015-04-08 2016-10-13 Sandia Corporation In Vivo Extraction of Interstitial Fluid Using Hollow Microneedles
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
WO2017045031A1 (en) 2015-09-18 2017-03-23 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
EP3355981B1 (en) 2015-09-28 2025-11-19 Vaxxas Pty Limited Microprojection arrays with enhanced skin penetrating properties and methods thereof
BR112018006488B1 (pt) * 2015-10-06 2024-03-12 Janssen Vaccines & Prevention B.V. Métodos para prevenir a degradação induzida por plástico de biológicos
EP3511318A1 (en) 2015-10-28 2019-07-17 Ajinomoto Co., Inc. Immunostimulating agent
US10722570B2 (en) * 2015-11-27 2020-07-28 Nitto Denko Corporation Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation
CN108289948A (zh) * 2015-11-27 2018-07-17 日东电工株式会社 口腔内给药用疫苗药物组合物和口腔内给药用疫苗药物组合物的制造方法
WO2017090767A1 (ja) * 2015-11-27 2017-06-01 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
CN113181106A (zh) * 2016-01-11 2021-07-30 沃达瑞公司 微针组合物及其使用方法
RU2018134360A (ru) 2016-03-01 2020-04-01 Джорджия Тек Рисёч Корпорейшн Микроигольные частицы, композиции и способы лечения и доставки представляющего интерес вещества
WO2018176102A1 (en) 2017-03-31 2018-10-04 Vaxxas Pty Limited Device and method for coating surfaces
CA3065371A1 (en) 2017-06-13 2018-12-20 Vaxxas Pty Limited Quality control of substrate coatings
AU2018309562A1 (en) 2017-08-04 2020-02-20 Vaxxas Pty Limited Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP)
AU2018315629B2 (en) * 2017-08-10 2025-06-26 Vaxxas Pty Limited Differential coating of microprojections and microneedles on arrays
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CA3130036A1 (en) * 2019-02-15 2020-08-20 Serum Institute Of India Pvt Ltd. Live attenuated influenza vaccine composition and process for preparation thereof
JP7176100B2 (ja) * 2019-03-28 2022-11-21 富士フイルム株式会社 インフルエンザワクチンを含有するマイクロニードルアレイ及びマイクロニードルアレイの製造方法
CN113874067A (zh) * 2019-03-29 2021-12-31 瓦克萨斯私人有限公司 用于疫苗的高密度微突出物阵列贴片
CA3159272A1 (en) * 2019-11-22 2021-05-27 Veradermics Incorporated Microneedle patch for immunostimulatory drug delivery
CN111154833B (zh) * 2020-01-03 2022-08-23 浙江夸克生物科技有限公司 一种α-L-岩藻糖苷酶测定试剂盒
US20230233373A1 (en) * 2020-06-11 2023-07-27 Aquavit Pharmaceuticals, Inc. Methods and compositions for delivering bioactive compositions to ocular tissue using microneedle devices
CN117355356A (zh) * 2021-03-23 2024-01-05 韦瑞德米克斯公司 皮肤病症的病灶周围治疗
JP2024543125A (ja) * 2021-11-25 2024-11-19 オレクソ・アクチエボラゲット バイオ医薬品化合物を含む医薬組成物
WO2025013783A1 (ja) * 2023-07-07 2025-01-16 ナガセヴィータ株式会社 タンパク質の変性抑制用組成物
WO2025222045A1 (en) * 2024-04-17 2025-10-23 Micron Biomedical, Inc. Microneedle devices for vaccinations with enhanced delivery and acceptance

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
AU767122B2 (en) 1998-06-10 2003-10-30 Georgia Tech Research Corporation Microneedle devices and methods of manufacture and use thereof
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6623457B1 (en) 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US9302903B2 (en) 2000-12-14 2016-04-05 Georgia Tech Research Corporation Microneedle devices and production thereof
US6887484B2 (en) * 2001-07-31 2005-05-03 Posco Vaccine composition containing a promoter peptide
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
AU2003275311A1 (en) 2002-09-16 2004-04-30 Sung-Yun Kwon Solid micro-perforators and methods of use
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
AU2004251699A1 (en) 2003-06-04 2005-01-06 Georgia Tech Research Corporation Drilling microneedle device
US9744227B2 (en) 2004-06-02 2017-08-29 Universal Stabilization Technologies, Inc. Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals and methods for formulation thereof
GB0416694D0 (en) * 2004-07-27 2004-09-01 Univ Strathclyde Process for preparing microcrystals
US20080269666A1 (en) 2005-05-25 2008-10-30 Georgia Tech Research Corporation Microneedles and Methods for Microinfusion
WO2006138719A2 (en) 2005-06-17 2006-12-28 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
HRP20110803T1 (hr) 2005-09-16 2011-11-30 Merial Ltd. Stabilizatori za cjepiva osušena zamrzavanjem
US20090182306A1 (en) 2006-07-21 2009-07-16 Georgia Tech Research Corporation Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal
KR20090128463A (ko) 2007-03-09 2009-12-15 오츠카 세이야쿠 가부시키가이샤 인플루엔자 백신 함유 동결 건조 제제, 및 그의 제조 방법
WO2009048607A1 (en) 2007-10-10 2009-04-16 Corium International, Inc. Vaccine delivery via microneedle arrays
GB0725018D0 (en) 2007-12-21 2008-01-30 Univ Cardiff Monitoring system for microneedle delivery
MX2010009351A (es) 2008-02-25 2011-03-04 Novavax Inc Particulas similares a virus cristalizadas con azucar.
ES2615390T3 (es) * 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2010001671A1 (ja) 2008-06-30 2010-01-07 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによるインフルエンザワクチンの奏功性を上昇させる方法
RU2577698C2 (ru) * 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
WO2011014794A1 (en) * 2009-07-31 2011-02-03 Paxvax, Inc. Adenoviral-based vectors
US20110243988A1 (en) * 2009-10-01 2011-10-06 Aridis Pharmaceuticals Methods and Compositions for Stabilization of a Virus Vaccine
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
ES2543795T3 (es) 2010-03-31 2015-08-21 Stabilitech Ltd. Estabilización de partículas virales
CA2796593C (en) 2010-04-15 2020-12-15 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery
GB201007207D0 (en) 2010-04-29 2010-06-16 Univ Cork Method
JP5976639B2 (ja) 2010-06-01 2016-08-23 ノバルティス アーゲー インフルエンザワクチン抗原の濃縮および凍結乾燥
WO2011156641A2 (en) 2010-06-09 2011-12-15 Kaspar Roger L Microneedle arrays for active agent delivery
JP5808102B2 (ja) 2010-07-22 2015-11-10 コスメディ製薬株式会社 抗原を含有する経皮免疫製剤およびその製造方法
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
JP5558311B2 (ja) 2010-10-27 2014-07-23 株式会社バイオセレンタック ワクチン抗原表皮デリバリー用溶解性３層マイクロニードル・アレイ・パッチ
WO2012103257A2 (en) 2011-01-25 2012-08-02 The Regents Of The University Of California Transcutaneous multimodal delivery systems
US20140287043A1 (en) * 2011-04-21 2014-09-25 Trustees Of Tufts College Compositions and methods for stabilization of active agents
KR102374576B1 (ko) 2011-05-17 2022-03-15 솔리제닉스, 인크. 열안정성 백신 조성물 및 그의 제조방법
US20130096532A1 (en) 2011-10-17 2013-04-18 Rutgers, The State University Of New Jersey Polymer-Based Micro-Needle Array Designs, Fabrication Processes, and Methods of Use Thereof for Drug Delivery
US9675675B2 (en) * 2011-11-30 2017-06-13 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
WO2013152092A1 (en) 2012-04-03 2013-10-10 Theraject, Inc. Soluble microneedle arrays for buccal delivery of vaccines
WO2014004462A1 (en) 2012-06-25 2014-01-03 Flugen, Inc. Multiple drug delivery device
CA2906945A1 (en) 2013-03-15 2014-09-18 Incube Labs, Llc Multi-stage biodegradable drug delivery platform
NZ731659A (en) 2014-11-03 2018-10-26 Merial Inc Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus

Also Published As

Publication number Publication date
RU2720808C2 (ru) 2020-05-13
JP7358068B2 (ja) 2023-10-10
CN105579059B (zh) 2020-07-31
CN105579059A (zh) 2016-05-11
JP2016535065A (ja) 2016-11-10
US20160220483A1 (en) 2016-08-04
EP3041504A1 (en) 2016-07-13
CA2923010C (en) 2022-08-30
RU2016111354A (ru) 2017-10-09
JP2019163271A (ja) 2019-09-26
US10736840B2 (en) 2020-08-11
CA2923010A1 (en) 2015-03-12
JP6611720B2 (ja) 2019-11-27
EP3041504B1 (en) 2021-08-25
EP3041504A4 (en) 2018-02-21
WO2015034924A1 (en) 2015-03-12
RU2016111354A3 (cg-RX-API-DMAC7.html) 2018-07-16

Similar Documents

Publication Publication Date Title
ES2897659T3 (es) Formulaciones de vacunas térmicamente estables, procesos y microagujas que incluyen las formulaciones de vacunas
Dumpa et al. Stability of vaccines
Kim et al. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity
Kim et al. Formulation of microneedles coated with influenza virus-like particle vaccine
Amorij et al. Development of stable influenza vaccine powder formulations: challenges and possibilities
KR102136036B1 (ko) 비강내 전달을 위한 방법 및 조성물
ES2673823T3 (es) Formulaciones de alfavirus y de partículas de replicones de alfavirus y métodos relacionados
RU2560675C2 (ru) Стабилизирующий эксципиент для вакцины с инактивированными целыми вирусами
US11918646B2 (en) Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CA2680193C (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
JP2015509529A (ja) 乾燥された生物学的材料を安定化するための方法及び組成物
Scherließ et al. Induction of protective immunity against H1N1 influenza A (H1N1) pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates
KR20180041237A (ko) Vlp 안정화된 백신 조성물
EP3127550A1 (en) Stabilizing composition for dry formulation of virus
US20250057936A1 (en) Vaccine composition
ES2731636T3 (es) Composición adyuvante que contiene citrulina
Wang et al. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery
JP7602457B2 (ja) ペプチド核酸を基盤としたアジュバント
US20230115214A1 (en) Dry powder compositions of oil-in-water (o/w) emulsion adjuvanted vaccines
Beukema Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s
ES2788324T3 (es) Métodos y composiciones para estabilizar materiales biológicos secos
WO2024236132A1 (en) Formulations to stabilize virus-based therapeutics
Soema Formulation of influenza T cell peptides: in search of a universal influenza vaccine
Bajrovic Development and Characterization of Thermostable Thin Films as a Novel Vaccine Dosage Form
Edens MEASLES AND POLIO VACCINATION USING A MICRONEEDLE PATCH TO INCREASE VACCINATION COVERAGE IN THE DEVELOPING WORLD